Hepatocellular carcinoma: insights in the biological treatment beyond sorafenib

Area of Science:

• Hepatology
• Oncology
• Translational Medicine

Background:

• Hepatocellular carcinoma (HCC) incidence and mortality are rising globally.
• Current standard systemic treatment for advanced HCC is sorafenib, a multi-kinase inhibitor.
• Numerous clinical trials are investigating novel therapies for first- and second-line treatment.

Purpose of the Study:

• To educate physicians on the mechanisms of action of emerging biological therapies for HCC.
• To provide an evidence-based algorithm for selecting optimal clinical trials for individual HCC patients.
• To stratify trial selection based on clinical and biological indicators.

Main Methods:

• Review of current literature on novel HCC therapies.
• Categorization of therapies including antiangiogenic agents, c-MET inhibitors, and immune modulators.
• Analysis of combination strategies involving chemotherapy and sorafenib.
• Exploration of cellular metabolism and mTOR inhibitors.
• Inclusion of other multi-kinase inhibitors.

Main Results:

• Detailed overview of diverse therapeutic strategies beyond sorafenib.
• Explanation of the biological rationale and mechanisms for each therapy class.
• Identification of potential patient subgroups who may benefit from specific trials.
• Structured approach to integrating new agents into treatment paradigms.

Conclusions:

• Advanced HCC treatment remains a significant clinical challenge.
• Personalized selection of clinical trials is crucial for potentially improving patient survival and clinical status.
• Understanding novel therapeutic mechanisms aids in optimizing patient management.